Advancing Medicines for a Brighter Future
Developing a pipeline of products aimed at diseases with unmet medical need
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programmes include MTX110, which is being studied in aggressive rare/orphan brain cancer indications, and tolimidone which is under development as a novel agent for the treatment of type 1 diabetes.
MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and potentially avoiding systemic toxicity.
Tolimidone is an orally delivered, potent and selective inhibitor of lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent.
Glioblastoma is the most common and devastating primary malignant brain tumour in adults
Our lead candidate, MTX110, is being studied in multiple serious and aggressive brain cancer indications including recurrent glioblastoma and diffuse midline glioma.
Biodexa Pharmaceuticals PLC is listed on NASDAQ: BDRX. Visit our investor resources for shareholder information and latest news and reports.
Reports & Presentations